U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer – Eli Lilly and Company

1. U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer  Eli Lilly and Company
2. US FDA approves Eli Lilly’s therapy for metastatic breast cancer  MarketScreener
3. Recon: RFK Jr. launches review of mifepristone; FDA approves Lilly’s advanced breast cancer drug  Regulatory Affairs Professionals Society | RAPS
4. Eli Lilly’s oral SERD Inluriyo passes muster with FDA in breast cancer  Fierce Pharma
5. US FDA Approves Eli Lilly’s Therapy for Advanced Breast Cancer  U.S. News & World Report

Continue Reading